Start Your Search
Poster Display session (Friday) (ID 65)
- Event: ELCC 2018
- Type: Poster Display session
- Presentations: 1
- Coordinates: 4/13/2018, 12:30 - 13:00, Hall 1
37P - Epidemiology and management of bronchopulmonary carcinoma in eastern Morocco of 738 cases (ID 217)
12:30 - 13:00 | Author(s): M. Bellaoui
In Morocco, bronchopulmonary cancer (CBP) is a major healthcare problem whose main etiological factor is tobacco. However, in the Eastern Kingdom region no study has been done on the epidemiological characteristics, pathological, clinical, molecular and therapeutic aspects of CBP.
This is a descriptive retrospective study aimed at determine the epidemiological, pathological, clinical and therapy of CBP of patients at the Regional Oncology Center (ROC) Hassan II Oujda.
The study population consisted of 738 patients, 671 men and 67 women. The mean age was 59.1 ± 11.9 years (median = 58 years). Smokers are mostly men and represent 87% of patients. Average smoking consumption was 37.58 ± 20.85-pack years with an average duration of 30.92 ± 11.18 years. The symptoms that prompted the consultation were: cough in 49.59% of cases, chest pain in 45.39% of cases, hemoptysis in 32.11% of cases, dyspnea in 30.89% of cases. Adenocarcinoma was the predominant histological type (47%) followed by epidermoid carcinomas (27%) and small cell carcinomas (13%). Involvement of the right lung was frequent (55%), 36% of the lesions involved the lobe upper right. Almost all patients (97%) were diagnosed in advanced stages (III and IV). In this series, 65% of patients were treated with chemotherapy, 31% with radiotherapy and surgical treatment was only done in 6% of cases.
This study reports, for the first time, the epidemiological data, pathology, clinical characteristics and therapy of CBP in the Eastern Region of Morocco for a period of 10 years (2005–2014). It was found that the diagnosis is often made at a late stage of the disease, hence the need for early detection and prevention based on the fight against tobacco.
Clinical trial identification:
Legal entity responsible for the study:
Genetic Department, Faculty of Medicine Oujda Morocco
Has not received any funding
All authors have declared no conflicts of interest.
Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.